Not yet recruiting NCT07753265

A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine

Early Phase I Interventional Herpse Zoster

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: live-attenuated zoster vaccine.
Who it may be relevant to: Registry conditions: Herpse Zoster. Basic parameters: from 50 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Center list to be confirmed — check the primary protocol.
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.

Biological live-attenuated zoster vaccine
one dose of live-attenuated zoster vaccine to the particpent only administered one dose of recombinant zoster vaccine

Age ≥ 50 years old;
The participant can provide personal informed consent and sign the informed consent form;
temperature ≤ 37.0℃ on the day of administration;
capable of complying with the requirements of the clinical trial protocol to complete the trial.

Subjects with immunodeficiency or immunosuppression caused by underlying diseases or treatments, including primary/acquired immunodeficiency (e.g., AIDS and other virus-induced immunodeficiency), hematologic malignancies (leukemia, lymphoma or other bone marrow/lymphoid neoplasms), ongoing immunosuppressive therapy, or radiotherapy/chemotherapy for malignancies.
Subjects with a history of allergic reaction to any component of the investigational product.
Subjects with acute infection or acute exacerbation of chronic infection (vaccination should be deferred).
Women of non-postmenopausal status with positive pregnancy test, pregnant or lactating women, or those planning pregnancy within 6 months.
Subjects with prior history of herpes zoster.
Subjects with prior receipt of varicella or herpes zoster vaccine.
Receipt of live-attenuated vaccines within 14 days, or subunit/inactivated vaccines within 7 days prior to study vaccination.
Receipt of whole-blood, plasma or immunoglobulin within 5 months before, or within 3 weeks after study vaccination.
Receipt of investigational drugs from other clinical trials within 1 month before study vaccination, current participation in another clinical trial, or planned use of investigational agents during study period.
Current or planned use of salicylates (including aspirin, diflunisal, etc.).
Uncontrolled abnormal blood pressure at screening (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg despite medication).

Subjects meeting contraindications or precautions specified in the product's prescribing information.

Any condition that, in the Investigator's opinion, may interfere with study evaluations.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Center list to be confirmed — check the primary protocol.

NCT: NCT07753265 · PFDP20260520